XENE Xenon Pharmaceuticals
- 40.450
- -0.130-0.32%
Xenon Pharmaceuticals News
Xenon Pharmaceuticals Insiders Sell US$4.5m Of Stock, Possibly Signalling Caution
Over the past year, many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) insiders sold a significant stake in the company which may have piqued investors' interest.
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Xenon Pharmaceuticals Price Target Maintained With a $62.00/Share by Needham
Xenon Pharmaceuticals Is Maintained at Buy by Citigroup
Xenon Pharmaceuticals Is Maintained at Buy by Citigroup
Citi: Maintains Xenon Pharmaceuticals (XENE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $62.00 to $60.00.
Citi: Maintains Xenon Pharmaceuticals (XENE.US) rating, adjusted from buy to buy rating, and adjusted the target price from $62.00 to $60.00.
Citigroup Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Citigroup analyst David Hoang maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and lowers the price target from $62 to $60.
Xenon Pharmaceuticals: A Strong Buy on Clinical Progress and Robust Financials
Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ...
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Wedbush: Maintaining the Xenon Pharmaceuticals (XENE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $51.00 to $50.00.
Wedbush: Maintaining the Xenon Pharmaceuticals (XENE.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $51.00 to $50.00.
Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating
Xenon Pharmaceuticals (XENE) has an average buy rating and a price target range of $45 to $63, according to analysts polled by Capital IQ.
Xenon Pharmaceuticals | 10-Q: Quarterly report
Xenon Pharma: Phase 3 Epilepsy Program Continues to Progress With Anticipated Completion of Patient Enrollment in X-TOLE2 in Late 2024 to Early 2025 >XENE
Xenon Pharma: Phase 3 Epilepsy Program Continues to Progress With Anticipated Completion of Patient Enrollment in X-TOLE2 in Late 2024 to Early 2025 >XENE
Xenon Pharmaceuticals: Engaging Investors With Regular Updates
Xenon Pharmaceuticals: Q1 Earnings Snapshot
Xenon Pharmaceuticals Q1 2024 Adj EPS $(0.62) Beats $(0.66) Estimate
Xenon Pharmaceuticals (NASDAQ:XENE) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.66) by 6.06 percent.
Press Release: Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-
Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE
Xenon Pharmaceuticals 1Q Loss/Shr 62c >XENE
Xenon Pharmaceuticals to Highlight Advances at Health Care Conference
Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will presen
Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC
Analysis
Price Target
No Data
